A lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy.
Diabetologia
; 41(7): 839-43, 1998 Jul.
Article
in En
| MEDLINE
| ID: mdl-9686927
ABSTRACT
Untreated streptozotocin-diabetic (7 weeks duration) rats showed reductions (all p < 0.01; percentages in brackets) in motor and sensory nerve conduction velocity (MNCV; 14%, SNCV; 17%) and in sciatic nerve contents of nerve growth factor (NGF; 57%), substance P (SP; 53%) and neuropeptide Y (NPY; 39%). Treatment with a gamma-linolenic acid-alpha-lipoic acid conjugate (GLA-LA; 35 mg x day(-1) x rat(-1)) attenuated (p < 0.05) these reductions to MNCV (8%), SNCV (5%), NGF (19%), SP (23%), NPY (20%), such that the values in GLA-LA-treated diabetic rats did not differ significantly from those of control non-diabetic animals. Treatment with alpha-lipoic acid alone at 100 mg/kg i.p. was without effect on these variables except for NGF (33% reduction, p < 0.05) and treatment with the antioxidant, butylated hydroxytoluene (1.5% dietary supplement) did not affect any deficits. These data show that GLA-LA is effective in improving both electrophysiological and neurochemical correlates of experimental diabetic neuropathy.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Sciatic Nerve
/
Gamma-Linolenic Acid
/
Diabetes Mellitus, Experimental
/
Diabetic Neuropathies
/
Neural Conduction
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
Diabetologia
Year:
1998
Document type:
Article
Affiliation country:
United kingdom